Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L. Garfall(University of Pennsylvania), Carl H. June(Parker Institute for Cancer Immunotherapy)
Cited by 196
Related Papers
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
|JCI Insight|2018|279
Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells
|Proceedings of the National Academy of Sciences|2023|77
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
|Blood Cancer Discovery|2022|74
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
|Science Advances|2023|61